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a b s t r a c t
New imidazo[1,2-a]quinoxaline analogues have been synthesized in good yields via a bimolecular
condensation of 2-imidazole carboxylic acid, followed by a coupling with ortho-ﬂuoroaniline and
subsequent substitution on the imidazole ring by Suzuki Cross-coupling reaction using microwave
assistance. Antitumor activities of these derivatives were evaluated by growth inhibition of A375 cells in
vitro. All compounds exhibited high activities compared to imiquimod and fotemustine used as
references.
 2009 Elsevier Masson SAS. All rights reserved.
1. Introduction
In our previous studies [1–3], a general synthetic strategy has
been elaborated which can easily get access to three basic
heterocycles imidazo/pyrazoloquinoxalines. This method led us to
the intermediates which remain non-substituted on the
5-membered cycle with good yields. New imiquimod analogues in
the imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline and
pyrazolo[1,5-a]quinoxaline series have also been synthesised and
tested in vitro and in vivo for their anti-cancer activities.
Imiquimod, an imidazoquinoline amine, has been initially
approved for the topical treatment of external genital warts caused
byhumanpapillomavirus [4–6]. It has shownactivities towardbasal
cell carcinomas (BCC), actinic keratoses, and some melanoma
metastases [7–10]. Fotemustine is a third generation nitrosourea
which is used both inmelanoma and brain tumors [11]. However, its
clinical application is somewhat limited both by its toxicity and by
the resistance of melanoma cells [12]. BMS-345541, an imidazo[1,2-
a]quinoxaline derivative has shown important cytotoxic activities
onmelanoma in vitro and in vivo [13]. It was identiﬁed as a selective
inhibitor of IkB kinase that blocked NF-kB pathway [14].
EAPB0203, a new imidazoquinoxaline amine derivative
demonstrated signiﬁcant in vitro activities against the human
melanoma cell line A375, 110 and 45 times more active than fote-
mustine and imiquimod, respectively [1,2]. Tested in vivo in female
Swiss Nude mice, EAPB0203 caused a signiﬁcant decrease in tumor
(M4Be xenografts) growth compared to vehicle control and
fotemustine treatments [1,2].
Recently, EAPB0203 was evaluated in T-cell lymphomas and
HTLV-I associated adult T-cell leukaemia/lymphoma. EAPB0203
exhibits an important cytotoxicity in vitro on HTLV-I-infected CD4þ
T-cell lines HuT-102, MT-2, and C91-PL as well as HTLV-1-negative
malignant CD4þ T-cell lines CEM, Jurkat, HuT-78, and MOLT-4. The
imidazoquinoxaline derivative exhibits inhibition of cell prolifera-
tion, G2/M cell cycle arrest, and induction of apoptosis in HTLV-I
transformed and HTLV-I negative malignant T cells [15].
In continuation of our studies on the reactivity of nitrogen
heterocycles, we focused on the preparation of imidazo[1,2-a]qui-
noxaline derivatives using the new synthetic strategy described
previously [1,2]. To develop a convenient pathway in good agree-
ment with rapid pharmacomodulation, wewere interested in using
the Suzuki Cross-coupling reaction. The application of this coupling
to these series was reported on the bromo derivatives [16]. In this
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work, we turned our interest to study the incorporation of different
arylboronic acids on the cytotoxic activity, in order to afford
a variety of new derivatives of our lead compound EAPB0203.
2. Results
2.1. Chemistry
2.1.1. Library synthesis
For the preparation of the 1H-imidazo[1,2-a]quinoxaline deriv-
atives, the procedure presented in Scheme 1 was used. Carbonyl-
imidazole dimer 1 resulted from the bimolecular condensation of
the 2-imidazole carboxylic acid, in presence of thionyl chloride in
95% overall yield. Product 1was coupledwith ortho-ﬂuoroaniline to
give the intermediate 2, with a yield of 40%. The tricyclic compound
3was obtained via an intramolecular cyclization of 2 accomplished
under strong basic conditions with 80% yield. Treatment of
compound 3 with phosphorus oxychloride and N,N-diethylaniline
yielded to 80% of compound 4 which was coupled with methyl-
amine to give compound 5 with average yields of 93% [1,3]. The
bromination of compound 5 by N-bromosuccinimide led to
compound 6. The position of the bromine on the imidazole ringwas
conﬁrmed by n.O.e study. Utilizing the appropriate arylbronic acid
allowed for introduction of various groups on the imidazole ring of
compound 6 via Suzuki reaction in the presence of palladium
catalyst, basic conditions and under microwave assistance to give
compounds 7a–7n in good yields.
2.1.2. In vitro cytotoxic activity
All compounds were evaluated for their cytotoxic activity in
vitro against A375 human melanoma cell line by comparison with
imiquimod, fotemustine used as references and EAPB0203. Table 1
gives the IC50 values for all of the imidazo[1,2-a]quinoxaline
derivatives as determined by the microculture tetrazolium dye
assay. All the tested imidazo[1,2-a]quinoxalines caused a signiﬁcant
inhibition of cell growth, their cytotoxicities were superior to that
of imiquimod and fotemustine. Compounds 7d, 7k–7n were
considerably 10–100 times less active than the present EAPB0203
known to be 110 and 45 times more active than fotemustine and
imiquimod on humanmelanoma cell line (A375), respectively [1,2].
Compounds 7h–7j showed a similar activity to EAPB0203. Five
compounds 7b, 7c, 7e–7g are 7–9 times more potent against A375
than EAPB0203 (Table 1).
3. Discussion
The procedure presented in Scheme 1 was used to prepare the
imidazo[1,2-a]quinoxaline derivatives. This method not only
reduced the number of puriﬁcation steps but also led us to propose
a new common and efﬁcient route for the preparation of the
unsubstituted imidazo[1,2-a]quinoxalines on the imidazole core
starting from the unsubstituted carboxylic acid. This new strategy
also permitted the introduction of R substituent at the last steps of
the procedure with different commercial Suzuki cross-coupling
reagents using microwave assistance.
The exact chemical structure of these imidazo[1,2-a]quinoxaline
derivatives and the assignments of the position of substitution on
the heterocycle using 1H and 13C NMR data were described
previously [17].
In order to conﬁrm the bromine position on the imidazole ring,
we carried out a n.O.e study. The irradiation of H-9 at 9.10 ppm
showed a correlation with only one proton H-8 at 7.5 ppm and the
signal intensity of n.O.e effect was increased up to 15%. No
correlation was observed between H-9 and protons of the imid-
azole ring. The same results were obtained by irradiation of H-2 at
7.65 ppm. These results led us to conﬁrm that the bromine was in
the position 1 of the imidazole ring.
We reported previously [1,2] that EAPB0203 bearing phenethyle
as substituent at position 1 was a lead compound with an activity
against A375 cell line 110 times higher than fotemustine
(IC50¼173 mM)and45 timeshigher than imiquimod (IC50¼ 70 mM).
In this paper, replacement of phenethyle (EAPB0203) by phenyle
(compound 7a) on the imidazole ring resulted in no change in
cytotoxicity. The presence of the carbon chain (EAPB0203) between
the phenyl and imidazole core appeared to be less interesting, the
activity was not inﬂuenced by the ﬂexibility of the substituent on R
position. Introduction of an electron-donating group (compounds
7b, 7c, 7e, 7f) enhanced activity. This increase could be explained by
additional interaction type hydrogen bound with the biological
target. The substitution of an electron-withdrawing group on the
phenyl core (compounds 7k–7m) displayed decreased potency.
Themethoxy group at position 2 on the phenyl ring (compound 7d)
has proved to be less favorable than the 3 and 4 positions
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Scheme 1. Synthesis of 1H-imidazo[1,2-a]quinoxaline derivatives. Reagents and conditions: (a) SOCl2 reﬂux, 18 h; (b) NaHMDS, THF, 5 h; (c) NaH, DMA, reﬂux, 10 h; (d) POCl3,
reﬂux, 6 h; (e) EtOH, NHCH3, 20 h, rt; (f) NBS, CHCl3, reﬂux, 2 h; (g) arylboronic acid (R–B(OH)2), Pd(PPh3)4, Na2CO3, DME, MW (140 C, 20 min).
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(compounds 7b, 7c). No signiﬁcant differences were observed
between the pKa and log P calculated values (Table 1) of this series of
compounds which are all substituted by an amino group.
In summary, a new series of imidazo[1,2-a]quinoxaline deriva-
tives were synthesized with short reaction times by using micro-
wave assistance and catalysts. These compounds were evaluated
for their antitumor activities against human melanoma. These new
analogues demonstrated interesting antitumor activities effect on
A375 cell lines more potent than imiquimod and fotemustine. We
found promising lead compounds (7b, 7c, 7e, 7f, 7g), EAPB0203
analogues, which exhibited high activities up to 9 times more
potent for compound 7b (EAPB0503) than EAPB0203 (lead
compound) on human melanoma cell lines. EAPB0503 can be
considered as a new lead compound of the imidazo[1,2-a]qui-
noxaline series. Further studies are now in progress for the opti-
mization of these compounds. On the other hand, in vivo studies
will be complemented and documented to depict the antitumor
activities of this new lead (EAPB0503) in female Swiss mice
xenografted with human melanoma cell lines.
4. Experimental
4.1. Chemistry
All solvents and reagents were obtained from commercial
sources and used without further puriﬁcation unless indicated
otherwise. 1H and 13C NMR spectra were recorded using a Bruker
AC 300 spectrometer. Chemical shifts are reported in parts per
million (ppm) from the tetramethylsilane resonance in the
indicated solvent. Coupling constants are reported in Hertz (Hz),
spectral splitting partners are designed as follow: singlet (s);
doublet (d); triplet (t); multiplet (m). Column chromatography
was performed on Merck silica gel 60 (200–400 mesh).
Elemental analysis was carried out at the Microanalytical
Central Department (Montpellier, France). The microwave organic
synthesis was assisted by the Biotage initiator (France). Melting
points of solid compounds were measured by the Biocote
apparatus. pKa and log P values are calculated using the ACDLabs
software (Toronto, Canada).
4.1.1. Diimidazo[1,2-a]piperazine-5,10-dione (1)
The imidazole-2-carboxylic acid (5 g, 44.6 mmol) in suspension
in thionyl chloride (75 mL) was heated to reﬂux, under agitation for
18 h. The reaction mixture was cooled, then ﬁltered, washed with
toluene, and dried under high vacuum to obtain a yellow solid
(yield, 90–95%). M.p.: 164 C. 1H NMR (300 MHz, DMSO-d6) d: 8.85
(s, 2H); 8.2 (s, 2H). 13C NMR (300 MHz, DMSO-d6) d: 145.85, 144.95,
125.20, 120.15. Anal. calcd for C8H4N4O2: C, 51.07; H, 2.14; N, 29.78.
Found: C, 51.15; H, 2.21; N, 29.46.
4.1.2. (2-Fluoroaniline)-1H-imidazole-4-carboxamide (2)
To 2-ﬂuoroaniline (1.91 ml, 19.77 mmol) in THF (13 ml), cooled
in a 10 C bath, (45.2 ml, 45,2 mmol, 1.0 M) sodium bis-(trime-
thylsilyl)amide in THF was added. The mixture was stirred for 1 h,
and a suspension of 1 (1.77 g, 9.4 mmol) in THF (20 mL) was added
and allowed towarm to room temperature. Themixturewas stirred
for 2 h, and acetic acid was added to pH 7. The reaction mixturewas
concentrated in vacuum followed by the addition of water and
saturated NaHCO3. The solid was collected by ﬁltration, washed
withwater and cyclohexane, and dried under high vacuum to give 2
as a beige solid (yield, 40%). M.p.: 250 C. 1H NMR (300 MHz,
DMSO-d6) d: 8.12 (dd,1H), 7.92 (dd,1H), 6.92 (t,1H), 7.13 (t,1H), 7.07
(s, 2H). 19F NMR: 126. 13C NMR (300 MHz, DMSO-d6) d: 151.69,
150.92, 150.52, 130.14, 128.79, 126.96, 123.97, 121.03, 119.53, 115.03.
Anal. calcd for C10H8FN3O: C, 58.54; H, 3.93; N, 20.48C, 64,37; H,
6.13; N, 16.09. Found: C, 58.33; H, 3.55; N, 20.14.
4.1.3. Imidazo[1,2-a]quinoxaline-6-(5H)-one (3)
A mixture of 2 (2 g, 9.75 mmol) and sodium hydride (0.3 g,
1.17 mmol) in dimethylacetamide (80 mL) was heated to reﬂux for
6 h. The reaction mixture was then concentrated in vacuum fol-
lowed by the addition of water and saturated ammonium chloride.
The solid was collected by ﬁltration, washed with water, and dried
to give 3 (yield, 80%). M.p.: 322 C. 1H NMR (300 MHz, DMSO-d6)
Table 1
Imidazo[1,2-a]quinoxaline derivatives: formula, IC50 against A375 (human melanoma cell lines), pKa and log P calculated values.
N
N N
NHCH3
R
imidazo[1,2-a]quinoxaline 
Compounds R1 Formula IC50
a (mM) pKa* log P*
7a C6H5– C17H14N4 2.19 0.08 5.18 0.4 3.68 1.43
7b (EAPB0503) 3-OCH3–C6H4– C18H16N4O 0.20 0.09 5.10 0.4 3.45 1.43
7c 4-OCH3–C6H4– C18H16N4O 0.37 0.4 5.45 0.4 3.50 1.43
7d 2-OCH3–C6H4– C18H16N4O 122 25 4.89 0.4 3.35 1.43
7e 3-OC2H5–C6H4– C19H18N4O 0.30 0.01 5.11 0.4 3.98 1.43
7f 3-OH–C6H4– C17H14N4O 0.56 0.12 5.14 0.4 2.94 1.43
7g 3-Br–C6H4– C17H13BrN4 0.65 0.02 4.96 0.4 4.43 1.43
7h 3-CF3–C6H4– C18H13F3N4 1.28 0.18 4.86 0.4 4.66 1.43
7i 3-Cl–C6H4– C17H13ClN4 1.78 0.35 4.88 0.4 4.25 1.43
7j 3-COOH–C6H4– C18H14N4O2 3.47 0.55 5.28 0.4 3.36 1.43
7k 3-F–C6H4– C17H13F N4 24.9 0.27 4.88 0.4 3.71 1.43
7l 3-CN–C6H4– C18H13N5 27.0 2.2 4.83 0.4 3.12 1.43
7m 3-NO2–C6H4– C17H13N5O2 40.0 3.9 4.57 0.4 3.21 1.43
7n 3-(C4H3O)– C15H12N4O 74.1 3.1 5.21 0.4 2.99 1.43
EAPB0203 C6H5–(CH2)2– C19H18N4 1.57 0.56 5.61 0.4 4.91 1.42
Imiquimod 70.3 4.3
Fotemustine 173 24
*pKa and log P values are calculated using the ACDlabs software.
a IC50, concentration of the compound (mM) producing 50% cell growth inhibition after 96 h of drug exposure, as determined by the MTT assay. Each experiment was run at
least three times, and the results are presented as average values standard deviation.
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d: 9.4 (s, 1H), 8.2 (d, 1H), 7.8 (d, 1H), 7.31 (d, 1H), 7.1–7.3 (m, 3H).
13C NMR (300 MHz, DMSO-d6) d: 149.26, 139.11, 137.89, 132.43,
126.43, 123.94, 123.02, 119.40, 118.17, 115.42. Anal. calcd for
C10H7N3O: C, 64.86; H, 3.81; N, 22.69. Found: C, 64.44; H, 4.03; N,
22.98.
4.1.4. 6-Chloroimidazo[1,2-a]quinoxaline (4)
To 3 (1.42 g, 7.7 mmol), phosphorus oxychloride (10 mL) and
N,N-diethylaniline (1.6 mL) were added and the mixture was
heated to reﬂux for 2 h. The reaction mixture was concentrated
under vacuum, and the residue was cooled in an ice bath. Water
was added to the residue and neutralized with saturated NaHCO3.
The solid was collected by ﬁltration and puriﬁed by recrystallisation
from methanol to yield 4 as a white solid (yield, 80%). M.p.: 188 C.
1H NMR (300 MHz, DMSO-d6) d: 8.5 (s, 1H), 8.06 (d,1H), 7.56 (s, 1H),
7.35 (m, 1H), 7.25 (m, 2H). 13C NMR (300 MHz, DMSO-d6) d: 135.82,
132.19, 131.75, 130.4, 129.95, 127.12, 125.03, 115.67, 113.4. Anal. calcd
for C10H6N3Cl: C, 58.98; H, 2.97; N, 20.64. Found: C, 59.12; H, 2.76;
N, 20.45.
4.1.5. N-Methylimidazo[1,2-a]quinoxalin-4-amine (5)
Methylamine of a 40% (w/v) aqueous solution, was added
dropwise to a stirred solution of 4 (0.110 g, 0.54 mmol) in absolute
EtOH (10 mL) at room temperature. After 40 h, another portion of
methylamine (0.15 ml, 1.74 mmol) of a 40% (w/v) aqueous solution
was added and stirring was maintained for additional 3 h. The
solvent was removed under reduced pressure, and the residue was
dissolved in CH2Cl2 (10 mL). The organic fraction was successively
washed with 5% NaHCO3 (15 mL) and water (15 mL), dried
(Na2SO4), and concentrated under reduced pressure. The product
was puriﬁed by column chromatography on silica gel with C6H12–
EtOAc (70:30, v/v) as eluent to yield a white solid (yield, 93%). M.p.:
180 C. 1H NMR (300 MHz, DMSO-d6) d: 7.92 (s, 1H), 7.75 (dd, 1H),
7,65 (dd, 1H), 7.52 (s, 1H), 7.4 (t,1H), 7.25 (t, 1H), 6.15 (s, 1H), 3.25 (d,
3H). 13C NMR (300 MHz, DMSO-d6) d: 142.25, 139.17, 131.99, 129.4,
128.17, 127.2, 125.14, 124.34, 114.14, 113.89, 29.20. Anal. calcd for
C11H10N4 C, 66.65; H, 5.08; N, 28.26. Found: C, 66.26; H, 5.53; N,
28.23.
4.1.6. 1-Bromo-N-methylimidazo[1,2-a]quinoxalin-4-amine (6)
A solution of 5 (1.5 g, 7.5 mmol) and N-bromosuccinimide (1.5 g,
7.5 mmol) in CHCl3 (200 mL) was heated under reﬂux for 2 h. The
resulting solution was cooled, washed with 5% sodium hydrogen
carbonate (50 mL), dried and concentrated. The residue was puri-
ﬁed by recristallisation from chloroform to a white solid (1.18 g,
67%). M.p.: 202 C. 1H NMR (300 MHz, DMSO-d6) d: 9.10 (s, 1H), 7.75
(dd, 1H), 7,65 (dd, 1H), 7.4 (t,1H), 7.25 (t, 1H), 6.15 (s, 1H), 3.25 (d,
3H). 13C NMR (300 MHz, DMSO-d6) d: 141.97, 140.54, 138.85, 128.96,
127.78, 127.09, 126.03, 125.13, 113.86, 101.4, 29.20. Anal. calcd for
C11H9N4Br: C, 47.68; H, 3.27; N, 20.22. Found: C, 47.33; H, 3.53; N,
20.53.
4.2. General procedure for the Suzuki reaction
To a mixture of 6 (300 mg, 1.08 mmol) and Pd(PPh3) (63 mg,
0.05 mmol) in DME (15 mL) was added the corresponding aryl
boronic acid followed by the addition of sodium carbonate
(234 mg) in water (5 mL). The reaction was irradiated in a sealed
tube at 140 C for 20 min using a Biotage Initiator microwave
synthesizer. The reaction mixture was poured on water and
then extracted with dichloromethane (2 40 mL). The combined
organic extracts were washed with water (40 mL), dried and
concentrated to dryness under vacuo. The crude product was
puriﬁed by column chromatography (silica gel eluting with
dichloromethane).
4.2.1. N-Methyl-1-phenylimidazo[1,2-a]quinoxalin-4-amine (7a)
Phenylboronic acid (260 mg, 2.13 mmol). White solid (90%).
M.p.: 186 C. 1H NMR (300 MHz, CDCl3) d: 8.15 (s, 1H), 7.99 (dd, 1H),
7.52 (m, 8H), 5.7(s, 1H), 3.01 (d, 3H). 13C NMR (300 MHz, CDCl3) d:
142.86, 139.37, 131.13, 130.74, 129.67, 129.02, 126.77, 125.75, 124.90,
124.78, 124.47, 121.12, 114.96, 29.20. Anal. calcd for C17H14N4: C,
74.43; H, 5.14; N, 20.42. Found: C, 74.15; H, 5.46; N, 20.09.
4.2.2. 1-(3-Methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-
amine (7b) (EAPB0503)
3-Methoxyphenylboronic acid (329 mg, 2.16 mmol). White solid
(90%). M.p.: 168 C. 1H NMR (300 MHz, CDCl3) d: 9.04 (s, 1H), 8 (dd,
1H), 7.82 (m, 2H), 7.4 (m, 3H), 6.99 (d, 1H), 6.86 (s, 1H), 5.7 (s, 1H),
3.83 (s, 3 H), 2.88 (d, 3H). 13C NMR (300 MHz, CDCl3) d: 160.98,
142.86, 139.57, 131.13, 130.56, 129.5, 129.02, 128.4, 127.39, 124.9,
124.40, 122.10, 118.02, 114.96, 111.87, 108.08, 55.30, 29.20. Anal.
calcd for C18H16N4O: C, 71.04; H, 5.30; N, 18.41. Found: C, 71.40; H,
5.66; N, 18.09.
4.2.3. 1-(4-Methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-
amine (7c)
4-Methoxyphenylboronic acid (329 mg, 2.16 mmol). White solid
(95%). M.p.: 198 C. 1H NMR (300 MHz, CDCl3) d: 8.14 (s, 1H), 8.00
(d, 1H), 7.67 (m, 3H), 7.5 (m, 2H), 7.05 (m, 2H), 5.77 (s, 1H), 3.82 (s,
3H), 2.99 (s, 3H). 13C NMR (300 MHz, CDCl3) d: 158.05, 142.86,
139.57, 131.13, 129.61, 129.02, 125.96, 125.68, 124.47, 124.02, 121.12,
114.96, 113.35, 57.83, 29.20. Anal. calcd for C18H16N4O: C, 71.04; H,
5.30; N, 18.41. Found: C, 71.18; H, 5.58; N, 18.13.
4.2.4. 1-(2-Methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-
amine (7d)
2-Methoxyphenylboronic acid (329 mg, 2.16 mmol). Beige solid
(94%). M.p.: 180 C. 1H NMR (300 MHz, CDCl3) d: 8.1 (d, 1H), 7.60 (m,
3H), 7.48 (t, 1H), 7.30 (m, 4H), 5.74 (s, 1H), 3.85 (s, 3H), 3.00 (s, 3H).
13C NMR (300 MHz, CDCl3) d: 153.81, 142.74, 139.57, 131.64, 131.13,
129.02, 128.44, 127.58, 124.45, 124.28, 121.37, 118.02, 114.86, 11.98,
55.32, 29.20. Anal. calcd for C18H16N4O: C, 71.04; H, 5.30; N, 18.41.
Found: C, 70.98; H, 5.12; N, 18.22.
4.2.5. 1-(3-Ethoxyphenyl)- N-methylimidazo[1,2-a]quinoxalin-4-
amine (7e)
3-Ethoxyphenylboronic acid (360 mg, 2.17 mmol). White solid
(52%). M.p.: 162 C. 1H NMR (300 MHz, CDCl3) d: 8.34 (s, 1H), 8.02
(d,1H), 7.83 (d,1H), 7.67 (t,1H), 7.5 (m, 2H), 6.96 (d,1H), 6.85 (s,1H),
5.74 (s, 1H), 3.89 (m, 2H), 2.89 (s, 3H), 1.38 (t, 3H). 13C NMR
(300 MHz, CDCl3) d: 161.36, 142.86, 139.57, 131.13, 130.22, 129.5,
129.02, 128.41, 127.05, 124.9, 122.1, 118.02, 114.96, 113.77, 108.12,
63.8, 29.2,15.2. Anal. calcd for C19H18N4O: C, 71.68; H, 5.70; N,17.60.
Found: C, 71.43; H, 5.56; N, 17.39.
4.2.6. 1-(3-Hydroxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-
amine (7f)
3-Hydroxyphenylboronic acid (329 mg, 2.16 mmol). White solid
(85%). M.p.: 278 C. 1H NMR (300 MHz, CDCl3) d: 8.33 (s, 1H), 7.99
(d,1H), 7.79 (d,1H), 7.70 (m, 2H), 7.67 (t, 1H), 7.50 (m, 3H), 6.857 (m,
2H), 3.02 (s, 3H). 13C NMR (300 MHz, CDCl3) d: 160.07, 142.86,
139.57, 131.46, 131.13, 130.35, 129.63, 129.02, 127.64, 126.78, 125.39,
124.9, 124.40, 122.83, 120.71, 114.86, 114.54, 29.02. Anal. calcd for
C17H14N4O: C, 70.33; H, 4.86; N, 19.30. Found: C, 70.49; H, 5.19; N,
19.09.
4.2.7. 1-(3-Bromophenyl)- N-methylimidazo[1,2-a]quinoxalin-4-
amine (7g)
3-Bromophenylboronic acid (435 mg, 2.16 mmol). Yellow solid
(78%). M.p.: 144 C. 1H NMR (300 MHz, CDCl3) d: 8.18 (s, 1H), 7.90
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(m, 2H), 7.67 (t, 1H), 7.50 (m, 2H), 7.45 (m, 3H), 5.74 (s, 1H), 2.98 (s,
3H). 13C NMR (300 MHz, CDCl3) d: 142.86, 139.57, 132.86, 131.13,
130.53, 129.63, 129.03, 127.64, 126.78, 125.39, 124.90, 124.30,
122.93, 120.71, 114.96, 29.20. Anal. calcd for C17H13 Br N4: C, 57.81;
H, 3.71; N, 15.86. Found: C, 58.05; H, 3.55; N, 15.99.
4.2.8. 1-(3-Triﬂuoromethylphenyl)- N-methylimidazo[1,2-
a]quinoxalin-4-amine (7h)
3-Triﬂuoromethylphenylboronic acid (411 mg, 2.16 mmol).
White solid (98%). M.p.: 210 C. 1H NMR (300 MHz, CDCl3) d: 8.14 (s,
1H), 8.10 (s, 1H), 8.02 (m, 2H), 7.85 (d, 1H), 7.60 (m, 2H), 7.48 (t, 1H),
5.74 (s, 1H), 2.96 (s, 3H). 13C NMR (300 MHz, CDCl3) d: 142.86,
139.57, 132.62, 132.30, 132.02, 131.60, 131.13, 129.02, 128.86, 124.90,
124.47, 122.51, 121.59, 120.40, 114.86, 114.54, 29.02. Anal. calcd for
C18H13N4F3: C, 63.16; H, 3.83; N, 16.65. Found: C, 63.03; H, 3.76; N,
16.74.
4.2.9. 1-(3-Chlorophenyl)-N-methylimidazo[1,2-a]quinoxalin-4-
amine (7i)
3-Chlorophenylboronic acid (339 mg, 2.16 mmol). Yellow solid
(63%). M.p.: 188 C. 1H NMR (300 MHz, CDCl3) d: 8.48 (s, 1H), 8.02
(d, 1H), 7.67 (t, 1H), 7.58 (m, 2H), 7.49 (m, 3H), 7.10 (s, 1H), 5.74 (s,
1H), 2.81 (s, 3H). 13C NMR (300 MHz, CDCl3) d: 142.86, 139.57,
135.86, 131.13, 130.50, 130.16, 129.76, 129.36, 129.02, 126.68, 124.9,
124.46, 123.39, 122.96, 121.74, 114.96, 29.15. Anal. calcd for
C17H13ClN4: C, 66.13; H, 4.24; N, 11.48. Found: C, 66.35; H, 4.01; N,
11.25.
4.2.10. 1-(3-Carboxyphenyl)- N-methylimidazo[1,2-a]quinoxalin-4-
amine (7j)
3-Carboxyphenylboronic acid (357 mg, 2.16 mmol). Orange
solid (87%). M.p.: 130 C. 1H NMR (300 MHz, CDCl3) d: 8.41 (d, 1H),
8.26 (s,1H), 8.01 (m, 2H), 7.80 (m, 4H), 7.58 (m, 2H), 7.47 (t,1H), 2.95
(s, 3H). 13C NMR (300 MHz, CDCl3) d: 167.35, 142.86, 139.54, 131.88,
131.13, 130.34, 129.02, 128.76, 127.1, 126.72, 124.9, 124.47, 122.51,
122.38, 114.96, 29.20. Anal. calcd for C18H14N4O2: C, 67.92; H, 4.43;
N, 17.60. Found: C, 67.72; H, 4.35; N, 17.63.
4.2.11. 1-(3-Fluorophenyl)- N-methylimidazo[1,2-a]quinoxalin-4-
amine (7k)
3-Fluorophenylboronic acid (303 mg, 2.16 mmol). Yellow solid
(66%). M.p.: 220 C. 1H NMR (300 MHz, CDCl3) d: 8.22 (s, 1H), 7.98
(d, 1H), 7.59 (m, 3H), 7.48 (m, 2H), 7.22 (s, 1H), 7.03 (d, 1H), 5.74 (s,
1H), 2.96 (s, 1H). 13C NMR (300 MHz, CDCl3) d: 163.95, 142.86,
139.57, 132.57, 132.15, 131.13, 129.02, 128.63, 126.77, 124.90,
124.47, 121.59, 115.29, 114.96, 111.90, 111.36, 29.20. Anal. calcd for
C17H13 F N4: C, 69.85; H, 4.48; N, 19.17. Found: C, 69.79; H, 4.48; N,
18.97.
4.2.12. 1-(3-Cyanophenyl)- N-methylimidazo[1,2-a]quinoxalin-4-
amine (7l)
3-Cyanophenylboronic acid (351 mg, 2.16 mmol). Beige solid
(84%). M.p.: 249 C. 1H NMR (300 MHz, CDCl3) d: 8.41 (s,1H), 8.13 (d,
1H), 8.00 (d,1H), 7.77 (d, 1H), 7.64 (m, 3H), 7.51 (m, 2H), 5.77 (s, 1H),
2.76 (s, 3H). 13C NMR (300 MHz, CDCl3) d: 142.86, 139.57, 132.25,
131.64, 131.13, 130.04, 129.02, 128.70, 128.67, 127.96, 127.41, 124.90,
124.47, 119.70, 114.96, 113.80, 29.20. Anal. calcd for C18H13N5: C,
72.23; H, 4.38; N, 23.40. Found: C, 72.01; H, 4.71; N, 23.25.
4.2.13. 1-(3-Nitrophenyl)- N-methylimidazo[1,2-a]quinoxalin-4-
amine (7m)
3-Nitrophenylboronic acid (399 mg, 2.16 mmol). Yellow solid
(95%). M.p.: 236 C. 1H NMR (300 MHz, CDCl3) d: 8.21 (s, 1H), 8.01
(d, 1H), 7.70 (m, 2H), 7.58 (d, 1H), 7.40 (m, 2H), 7.17 (m, 2H), 5.17 (s,
1H), 3.01 (s, 3H). 13C NMR (300 MHz, CDCl3) d: 147.62, 142.86,
139.57, 131.19, 131.13, 129.02, 127.32, 127.16, 126.99, 126.43, 124.90,
124.66, 124.40, 122.75, 120.76, 114.96, 29.20. Anal. calcd for
C17H13N5O2: C, 63.94; H, 4.10; N, 21.93. Found: C, 64.13; H, 3.89; N,
21.66.
4.2.14. 1-(3-Furan-N-methylimidazo[1,2-a]quinoxalin-4-amine
(7n)
3-Furanboronic acid (243 mg, 2.16 mmol). White solid (96).
M.p.: 190 C. 1H NMR (300 MHz, CDCl3) d: 8.24 (s, 1H), 7.90 (m, 3H),
7.83 (s, 1H), 7.62 (t, 1H), 7.50 (m, 2H), 7.12 (m, 2H), 6.98 (s, 1H), 5.74
(s, 1H), 4.85 (d, 1H), 2.85 (s, 3H). 13C NMR (300 MHz, CDCl3) d:
141.50, 137.73, 135.60, 130.13, 128.79, 128.02, 124.24, 123.70, 117.85,
116.09, 113.61, 107.72, 94.65, 29.20. Anal. calcd for C15H12N4O: C,
68.17; H, 4.58 N, 21.20. Found : C, 68.20 ; H, 4.56 ; N, 21.17.
4.3. Cell lines and culture techniques
Melanoma (A375) human cancer cell lines were obtained from
American Type Culture Collection (Rockville, Md., USA). Cells were
cultured in RPMI medium containing RPMI-1640 (Gibco Laborato-
ries, France), 10% heat-inactived (56 C) foetal bovine serum (FBS)
(Polylabo, Paris, France), 2 mM L-glutamine, 100 IU/ml penicillin G
sodium, 100 mg/ml streptomycin sulphate, and 0.25 mg/ml ampho-
tericin B. Cells were maintained in a humidiﬁed atmosphere of 5%
CO2 in air at 37 C.
4.4. In vitro cytotoxicity assay
Previously to the experiments, the number of cells by well, the
doubling time and the MTT concentration have been optimized. In
all the experiments, A375 cells were seeded at a ﬁnal concentration
of 5000 cells/well in 96-well microtiter plates and allowed to attach
overnight. After 20–24 h incubation, the medium was aspirated
carefully from the plates using a sterile Pasteur pipette, and cells
were exposed (i) to vehicle controls (1% DMSO/culture medium and
culture medium alone), (ii) fotemustine and imiquimod at concen-
trations of 104–1010 mM,diluted in the culturemedium, and (iii) to
the synthesized compounds (104–1010 mM)dissolved in amixture
1% DMSO/culture medium (v/v). After 96 h of incubation, 10 ml of
MTT solution in PBS (5 mg/ml, phosphate-buffer saline pH 7.3) was
added to each well, and the wells were incubated at 37 C for 4 h.
This colorimetric assay is based on the ability of live and metaboli-
cally unimpaired tumor-cell targets to reduce MTT to a blue for-
mazanproduct. At the end of the incubationperiod, the supernatant
was carefullyaspirated, then,100 ml of amixture of isopropyl alcohol
and 1 M hydrochloric acid (96/4, v/v) was added to each well. After
10 min of incubation and vigorous shaking to solubilize formazan
crystals, the optical density was measured at 570 nm in a microcul-
tureplate reader (DynatechMR5000, France). For eachassay, at least
three experiments were performed in triplicate.
The individual cell line growth curves conﬁrmed that all A375
lines in control medium remained in the log phase of cell growth
96 h after plating. Cell survival was expressed as percent of vehicle
control. The IC50 values deﬁned as the concentrations of drugs
which produced 50% cell growth inhibition; 50% reduction of
absorbance, were estimated from the sigmoidal dose–response
curves.
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